Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE

INTRODUCTION: We report safety and efficacy in patients treated with dimethyl fumarate (DMF) for ~9 years in ENDORSE. Lymphocyte analysis data are also reported. METHODS: Incidence of serious adverse events (SAEs), discontinuations due to adverse events (AEs), annualized relapse rate (ARR) and Expan...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ther Adv Neurol Disord
Asıl Yazarlar: Gold, Ralf, Arnold, Douglas L., Bar-Or, Amit, Fox, Robert J., Kappos, Ludwig, Chen, Chongshu, Parks, Becky, Miller, Catherine
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2020
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222239/
https://ncbi.nlm.nih.gov/pubmed/32426039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420915005
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller